Sudeep Pharma’s Q1FY27 profit rose 30% year-on-year to ₹40.6 crore, though revenue fell sequentially. While the Pharmaceutical, Food & Nutrition segment showed growth, the Specialty Ingredients division faced margin pressure. Consequently, Prabhudas Lilladher maintained a 'Reduce' rating with a target price of ₹855, citing high stock valuations and execution risks for upcoming projects.
Sudeep Pharma, which listed on the Indian stock exchanges in late 2025, reported a mixed financial performance for the first quarter of fiscal year 2027. The company's consolidated revenue stood at ₹158.3 crore, representing a 27% increase compared to the same period last year. However, the company experienced a 13% decline in revenue compared to the previous quarter. Similarly, consolidated net profit reached ₹40.6 crore, a 30% jump year-on-year, but a 17% decrease sequentially.
Segment Performance Divergence
The company’s performance was split between its two main business segments. The Pharmaceutical, Food & Nutrition (PFN) division acted as a key contributor, showing resilience with a 31% revenue increase year-on-year and 20% quarter-on-quarter. In contrast, the Specialty Ingredients (SI) segment faced significant challenges. This division saw its revenue drop by 46% quarter-on-quarter, accompanied by a sharp contraction in EBIT margins. This weakness was linked to softer demand in certain niche categories and logistical disruptions related to gas supply during the quarter.
Brokerage Perspective and Valuation
Following the results, brokerage firm Prabhudas Lilladher maintained its 'Reduce' rating on Sudeep Pharma, setting a target price of ₹855. The brokerage noted that while the company has growth potential, its current stock valuation—trading at roughly 45 times the estimated earnings for FY28—remains high compared to peers. The 'Reduce' rating reflects concerns regarding the sustainability of profit margins, especially given the volatility observed in the Specialty Ingredients business, and the potential for earnings to miss expectations.
Future Growth and Execution Risks
Sudeep Pharma is currently focused on its large-scale battery-grade pCAM project. The company confirmed that Phase 1 of this project is progressing as scheduled and is expected to be commissioned by April 2027. Additionally, there are plans to increase manufacturing capacity from 100 kilotons to 200 kilotons per annum.
Investors may monitor these expansion plans closely, as they carry inherent execution risks, such as potential delays or cost increases. Other factors that could impact the company's financial health include customer concentration—where a small group of top clients accounts for a large portion of revenue—and ongoing sensitivity to global supply chain and logistics costs. The company's ability to maintain stable margins in the Specialty Ingredients segment will be a key factor for shareholders to watch in the coming quarters.